Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
Introduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, altho...
- Autores:
-
Barrón-Barrón, Feliciano
Sánchez, Roberto P.
Arroyo-Hernández, Marisol
Blanco, Carolina
Zatarain-Barrón, Zyanya Lucia
Catalán, Rodrigo
Ramos-Ramírez, Maritza
Cardona-Mendoza, Andrés Felipe
Flores-Estrada, Diana
Arrieta, Oscar
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/5058
- Palabra clave:
- Checkpoint immune therapy
Pneumonitis
Radiotherapy
NSCLC
Lung cancer
Immune related adverse effects
- Rights
- openAccess
- License
- Attribution 4.0 International
id |
UNBOSQUE2_2347cb0d2427f9628527651a7616b74f |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/5058 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
dc.title.translated.spa.fl_str_mv |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
title |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
spellingShingle |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy Checkpoint immune therapy Pneumonitis Radiotherapy NSCLC Lung cancer Immune related adverse effects |
title_short |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
title_full |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
title_fullStr |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
title_full_unstemmed |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
title_sort |
Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy |
dc.creator.fl_str_mv |
Barrón-Barrón, Feliciano Sánchez, Roberto P. Arroyo-Hernández, Marisol Blanco, Carolina Zatarain-Barrón, Zyanya Lucia Catalán, Rodrigo Ramos-Ramírez, Maritza Cardona-Mendoza, Andrés Felipe Flores-Estrada, Diana Arrieta, Oscar |
dc.contributor.author.none.fl_str_mv |
Barrón-Barrón, Feliciano Sánchez, Roberto P. Arroyo-Hernández, Marisol Blanco, Carolina Zatarain-Barrón, Zyanya Lucia Catalán, Rodrigo Ramos-Ramírez, Maritza Cardona-Mendoza, Andrés Felipe Flores-Estrada, Diana Arrieta, Oscar |
dc.contributor.orcid.none.fl_str_mv |
Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471] |
dc.subject.keywords.spa.fl_str_mv |
Checkpoint immune therapy Pneumonitis Radiotherapy NSCLC Lung cancer Immune related adverse effects |
topic |
Checkpoint immune therapy Pneumonitis Radiotherapy NSCLC Lung cancer Immune related adverse effects |
description |
Introduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, although a connection between antitumor immuneresponses and irAEs has been suggested. In this study, we evaluated the developmentof ICIP in non-small cell lung cancer patients with prior radiotherapy, treated withimmunotherapy in the second-line.Methods:In this retrospective trial, we included patients treated with second-lineimmunotherapy at the National Cancer Institute in Mexico City from February 2015 toFebruary 2018. Clinical, radiological and treatment variables were evaluated accordingto the presence of ICIP as defined by the Common Terminology Criteria for AdverseEvents (4.0) in patients with or without a previous (≥months) history of radiotherapy.Results:Among 101 NSCLC patients who received treatment with ICIs, 22 patients(21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy(OR 6.04, 95% CI 2.03−18.0,p<0.001). Median progression free survival and overallsurvival were similar in patients who developed ICIP compared with those who did not,however, patients who presented grade≥2 ICIP had an increased risk of mortality (HR2.54, 95% CI 1.20−5.34,p= 0.014).Conclusion:In this real-world cohort of NSCLC patients treated with ICI, the historyof prior radiotherapy was associated with increased risk for ICIP development. Unlikeother irAEs, grade≥2 ICIP is an independent prognostic factor for decreased survivalin NSCLC patients. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-11-12T21:40:33Z |
dc.date.available.none.fl_str_mv |
2020-11-12T21:40:33Z |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.local.none.fl_str_mv |
Artículo de revista |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
format |
http://purl.org/coar/resource_type/c_6501 |
dc.identifier.issn.none.fl_str_mv |
2234-943X |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/5058 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3389/fonc.2020.570233 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
2234-943X instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/5058 https://doi.org/10.3389/fonc.2020.570233 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Frontiers in oncology, 2234-943X, Vol. 10, Nro. 29, 2020 |
dc.relation.uri.none.fl_str_mv |
https://www.frontiersin.org/articles/10.3389/fonc.2020.570233/full |
dc.rights.*.fl_str_mv |
Attribution 4.0 International |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess Acceso abierto |
dc.rights.creativecommons.none.fl_str_mv |
2020-09-29 |
rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf2 2020-09-29 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Frontiers Media S.A. |
dc.publisher.journal.spa.fl_str_mv |
Frontiers in oncology |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/667c4187-cc18-42fc-ab29-944a85beeeb8/download https://repositorio.unbosque.edu.co/bitstreams/836b9f8b-db54-468c-bab4-8317494b416c/download https://repositorio.unbosque.edu.co/bitstreams/aba3eac0-9d15-43d5-9757-c9a31677708d/download https://repositorio.unbosque.edu.co/bitstreams/7a3536dd-6bb6-456f-8fae-73b6536ed1e0/download https://repositorio.unbosque.edu.co/bitstreams/93162162-c675-4604-92ca-bcafd1116c97/download |
bitstream.checksum.fl_str_mv |
0175ea4a2d4caec4bbcc37e300941108 8a4605be74aa9ea9d79846c1fba20a33 e57d26e78f25f06bdb062d0ead01dcd7 afb55d74284c59ab1717c773e012d31e a23c3b710ba1cdffe67db467837edd4a |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1814100813053689856 |
spelling |
Barrón-Barrón, FelicianoSánchez, Roberto P.Arroyo-Hernández, MarisolBlanco, CarolinaZatarain-Barrón, Zyanya LuciaCatalán, RodrigoRamos-Ramírez, MaritzaCardona-Mendoza, Andrés FelipeFlores-Estrada, DianaArrieta, OscarCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]2020-11-12T21:40:33Z2020-11-12T21:40:33Z2234-943Xhttp://hdl.handle.net/20.500.12495/5058https://doi.org/10.3389/fonc.2020.570233instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengFrontiers Media S.A.Frontiers in oncologyFrontiers in oncology, 2234-943X, Vol. 10, Nro. 29, 2020https://www.frontiersin.org/articles/10.3389/fonc.2020.570233/fullAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2020-09-29Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyRisk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Checkpoint immune therapyPneumonitisRadiotherapyNSCLCLung cancerImmune related adverse effectsIntroduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, although a connection between antitumor immuneresponses and irAEs has been suggested. In this study, we evaluated the developmentof ICIP in non-small cell lung cancer patients with prior radiotherapy, treated withimmunotherapy in the second-line.Methods:In this retrospective trial, we included patients treated with second-lineimmunotherapy at the National Cancer Institute in Mexico City from February 2015 toFebruary 2018. Clinical, radiological and treatment variables were evaluated accordingto the presence of ICIP as defined by the Common Terminology Criteria for AdverseEvents (4.0) in patients with or without a previous (≥months) history of radiotherapy.Results:Among 101 NSCLC patients who received treatment with ICIs, 22 patients(21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy(OR 6.04, 95% CI 2.03−18.0,p<0.001). Median progression free survival and overallsurvival were similar in patients who developed ICIP compared with those who did not,however, patients who presented grade≥2 ICIP had an increased risk of mortality (HR2.54, 95% CI 1.20−5.34,p= 0.014).Conclusion:In this real-world cohort of NSCLC patients treated with ICI, the historyof prior radiotherapy was associated with increased risk for ICIP development. Unlikeother irAEs, grade≥2 ICIP is an independent prognostic factor for decreased survivalin NSCLC patients.CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908https://repositorio.unbosque.edu.co/bitstreams/667c4187-cc18-42fc-ab29-944a85beeeb8/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/836b9f8b-db54-468c-bab4-8317494b416c/download8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALFeliciano Barrón, Roberto Sánchez_2020.pdfFeliciano Barrón, Roberto Sánchez_2020.pdfapplication/pdf730560https://repositorio.unbosque.edu.co/bitstreams/aba3eac0-9d15-43d5-9757-c9a31677708d/downloade57d26e78f25f06bdb062d0ead01dcd7MD51THUMBNAILFeliciano Barrón, Roberto Sánchez_2020.pdf.jpgFeliciano Barrón, Roberto Sánchez_2020.pdf.jpgIM Thumbnailimage/jpeg12922https://repositorio.unbosque.edu.co/bitstreams/7a3536dd-6bb6-456f-8fae-73b6536ed1e0/downloadafb55d74284c59ab1717c773e012d31eMD54TEXTFeliciano Barrón, Roberto Sánchez_2020.pdf.txtFeliciano Barrón, Roberto Sánchez_2020.pdf.txtExtracted texttext/plain42471https://repositorio.unbosque.edu.co/bitstreams/93162162-c675-4604-92ca-bcafd1116c97/downloada23c3b710ba1cdffe67db467837edd4aMD5520.500.12495/5058oai:repositorio.unbosque.edu.co:20.500.12495/50582024-02-07 08:25:45.277http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |